Clinical observation of recombinant human endostatin combined with cisplatin in the treatment of pleural effusion of lung cancer
10.3760/cma.j.issn.1008-6706.2018.07.023
- VernacularTitle:重组人血管内皮抑制素联合顺铂治疗肺癌恶性胸腔积液的临床观察
- Author:
Xi CHEN
1
Author Information
1. 丽水市中医院呼吸肿瘤科
- Keywords:
Recombinant human vascular endothelin;
Cisplatin;
lung cancer;
Pleural effusion;
Clinical efficacy
- From:
Chinese Journal of Primary Medicine and Pharmacy
2018;25(7):902-905
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the clinical effect of recombinant human endostatin combined with cisplatin in the treatment of malignant pleural effusion of lung cancer.Methods 100 lung cancer patients with malignant pleural effusion were selected and divided into observation group and control group according to the random number table method,with 50 cases in each group.The control group was treated with cisplatin 40mg/m2 single-dose pleural perfusion.The observation group was treated with 40mg/m2 of cisplatin on the basis of 45mg of recombinant human endostatin.All the patients were treated twice a week,treatment for 3 weeks.The clinical efficacy,adverse reactions,the immune function indicators before and after treatment,quality of life improvement were compared between the two groups.Results (1) In the control group,l0 cases were cured,markedly effective in 24 cases,effective in 12 cases,the total effective rate was 92％.In the observation group,4 cases were cured,markedly effective in 14 cases,effective in 18 cases,the total effective rate was 72％,the difference between the two groups was statistically significant (x2 =9.15,P ＜ 0.05).(2) In the control group,15 cases occurred nausea and vomiting,12 cases of leukopenia,11 cases of neutropenia,10 cases of thrombocytopenia.In the observation group,4 cases of nausea and vomiting,14 cases of leukopenia,10 cases of neutropenia,14 cases of thrombocytopenia.There was no statistically significant difference between the two groups (x2 =10.24,P ＞ 0.05),but the number of adverse reactions in the observation group was less than that in the control group,which indicated that the safety of the observation group was high.(3) Before treatment,the CD4+,CD8+ and CD4+/CD8+ between the two groups had no statistically significant differences (t =0.03,0.26,0.67,all P ＞ 0.05).After treatment,the percentage of CD4+ and CD4+/CD8+ in the observation group were higher than those in the control group,the percentage of CDs+ in the observation group was lower than that in the control group,the differences were statistically significant (t =11.58,12.36,10.84,all P ＜0.05).(4) In the observation group,improved in 31 cases,stable in 10 cases,decreased in 9 cases.In the control group,improved in 25 cases,stable in 12 cases,decreased in 13 cases.There was in statistically significant difference between the two groups (x2 =2.30,P ＜ 0.05).Conclusion Recombinant human endostatin combined with cisplatin in the treatment of pleural effusion of lung cancer is significant,which can enhance the immune function of patients,improve the quality of life of patients,and with good safety,less adverse reactions.
